Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
Condition(s):Eosinophilic Myeloid Neoplasm; Hypereosinophilic SyndromeLast Updated:March 27, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Eosinophilic Myeloid Neoplasm; Hypereosinophilic SyndromeLast Updated:March 27, 2024Recruiting
Condition(s):Anemia, Aplastic; Blood Disease; AgranulocytosisLast Updated:May 13, 2016Completed
Condition(s):Infection; Neutropenia; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol SpecificLast Updated:August 10, 2018Withdrawn
Condition(s):Neutropenia; Breast Cancer; Lung Cancer; Non-Hodgkin’s Lymphoma; Ovarian CancerLast Updated:October 8, 2010Completed
Condition(s):Hypereosinophilic SyndromeLast Updated:March 4, 2008Completed
Condition(s):Neutropenia; Fever; CancerLast Updated:July 6, 2011Completed
Condition(s):Chemotherapy; NeutropeniaLast Updated:July 8, 2013Unknown status
Condition(s):Malignant Hemopathy; Duration of Neutropenia Following Chemotherapy > 10 DaysLast Updated:September 21, 2006Terminated
Condition(s):NeutropeniaLast Updated:May 10, 2011Completed
Condition(s):MBL-Deficient; NeutropeniaLast Updated:August 30, 2007Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.